Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.

The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).

The decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024.

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.

Amgen’s bispecific T-cell engager (BiTE) led to an ORR of 41% in patients with extensive-stage small cell lung cancer.

MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Multiple Sclerosis.

The Abu Dhabi Stem Cells Center (ADSCC) has developed clinical-grade induced pluripotent stem cells (iPSCs) that meet GMP protocols.

TCA-101 is under clinical development by TCR Cure Biopharma Technology and currently in Phase II for Endometrial Cancer.

The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.

Anti-CDH17 CAR-T Cells is under clinical development by UTC Therapeutics and currently in Phase I for Pancreatic Cancer.

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.